These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 30481287)

  • 1. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.
    Seiwert TY; Foster CC; Blair EA; Karrison TG; Agrawal N; Melotek JM; Portugal L; Brisson RJ; Dekker A; Kochanny S; Gooi Z; Lingen MW; Villaflor VM; Ginat DT; Haraf DJ; Vokes EE
    Ann Oncol; 2019 Feb; 30(2):297-302. PubMed ID: 30481287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience.
    Rosenberg AJ; Agrawal N; Pearson A; Gooi Z; Blair E; Cursio J; Juloori A; Ginat D; Howard A; Chin J; Kochanny S; Foster C; Cipriani N; Lingen M; Izumchenko E; Seiwert TY; Haraf D; Vokes EE
    Oral Oncol; 2021 Nov; 122():105566. PubMed ID: 34662771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose and Volume De-Escalation for Human Papillomavirus-Positive Oropharyngeal Cancer is Associated with Favorable Posttreatment Functional Outcomes.
    Foster CC; Seiwert TY; MacCracken E; Blair EA; Agrawal N; Melotek JM; Portugal L; Brisson RJ; Gooi Z; Spiotto MT; Vokes EE; Haraf DJ
    Int J Radiat Oncol Biol Phys; 2020 Jul; 107(4):662-671. PubMed ID: 32311416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.
    Marur S; Li S; Cmelak AJ; Gillison ML; Zhao WJ; Ferris RL; Westra WH; Gilbert J; Bauman JE; Wagner LI; Trevarthen DR; Balkrishna J; Murphy BA; Agrawal N; Colevas AD; Chung CH; Burtness B
    J Clin Oncol; 2017 Feb; 35(5):490-497. PubMed ID: 28029303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.
    Chen AM; Felix C; Wang PC; Hsu S; Basehart V; Garst J; Beron P; Wong D; Rosove MH; Rao S; Melanson H; Kim E; Palmer D; Qi L; Kelly K; Steinberg ML; Kupelian PA; Daly ME
    Lancet Oncol; 2017 Jun; 18(6):803-811. PubMed ID: 28434660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment.
    Rosenberg AJ; Izumchenko E; Pearson A; Gooi Z; Blair E; Karrison T; Juloori A; Ginat D; Cipriani N; Lingen M; Sloane H; Edelstein DL; Keyser K; Fredebohm J; Holtrup F; Jones FS; Haraf D; Agrawal N; Vokes EE
    BMC Cancer; 2022 Jan; 22(1):17. PubMed ID: 34980038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial.
    Misiukiewicz K; Gupta V; Miles BA; Bakst R; Genden E; Selkridge I; Surgeon JT; Rainey H; Camille N; Roy E; Zhang D; Ye F; Jia R; Moshier E; Bonomi M; Hwang M; Som P; Posner MR
    Oral Oncol; 2019 Aug; 95():170-177. PubMed ID: 31345387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial.
    Rosenberg AJ; Agrawal N; Juloori A; Cursio J; Gooi Z; Blair E; Chin J; Ginat D; Pasternak-Wise O; Hasina R; Starus A; Jones FS; Izumchenko E; MacCracken E; Wolk R; Cipriani N; Lingen MW; Pearson AT; Seiwert TY; Haraf DJ; Vokes EE
    JAMA Oncol; 2024 Jul; 10(7):923-931. PubMed ID: 38842838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck.
    Suntharalingam M; Kwok Y; Goloubeva O; Parekh A; Taylor R; Wolf J; Zimrin A; Strome S; Ord R; Cullen KJ
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1845-50. PubMed ID: 21601372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trials.
    Fakhry C; Zhang Q; Gillison ML; Nguyen-Tân PF; Rosenthal DI; Weber RS; Lambert L; Trotti AM; Barrett WL; Thorstad WL; Yom SS; Wong SJ; Ridge JA; Rao SSD; Spencer S; Fortin A; Raben D; Harris J; Le QT
    Cancer; 2019 Jun; 125(12):2027-2038. PubMed ID: 30913305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma.
    Ma DJ; Price KA; Moore EJ; Patel SH; Hinni ML; Garcia JJ; Graner DE; Foster NR; Ginos B; Neben-Wittich M; Garces YI; Chintakuntlawar AV; Price DL; Olsen KD; Van Abel KM; Kasperbauer JL; Janus JR; Waddle M; Miller R; Shiraishi S; Foote RL
    J Clin Oncol; 2019 Aug; 37(22):1909-1918. PubMed ID: 31163012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional Outcomes After De-escalated Chemoradiation Therapy for Human Papillomavirus-Positive Oropharyngeal Cancer: Secondary Analysis of a Phase 2 Trial.
    Hegde JV; Shaverdian N; Felix C; Wang PC; Veruttipong D; Hsu S; Riess JW; Rao SD; Daly ME; Chen AM
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):647-651. PubMed ID: 29246721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 Trial of De-intensified Chemoradiation Therapy for Favorable-Risk Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
    Chera BS; Amdur RJ; Tepper J; Qaqish B; Green R; Aumer SL; Hayes N; Weiss J; Grilley-Olson J; Zanation A; Hackman T; Funkhouser W; Sheets N; Weissler M; Mendenhall W
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):976-85. PubMed ID: 26581135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002).
    Yom SS; Torres-Saavedra P; Caudell JJ; Waldron JN; Gillison ML; Xia P; Truong MT; Kong C; Jordan R; Subramaniam RM; Yao M; Chung CH; Geiger JL; Chan JW; O'Sullivan B; Blakaj DM; Mell LK; Thorstad WL; Jones CU; Banerjee RN; Lominska C; Le QT
    J Clin Oncol; 2021 Mar; 39(9):956-965. PubMed ID: 33507809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De-intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive surgery for resectable HPV-positive oropharyngeal carcinoma.
    Howard J; Dwivedi RC; Masterson L; Kothari P; Quon H; Holsinger FC
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012939. PubMed ID: 30550641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
    Chera BS; Amdur RJ; Green R; Shen C; Gupta G; Tan X; Knowles M; Fried D; Hayes N; Weiss J; Grilley-Olson J; Patel S; Zanation A; Hackman T; Zevallos J; Blumberg J; Patel S; Kasibhatla M; Sheets N; Weissler M; Yarbrough W; Mendenhall W
    J Clin Oncol; 2019 Oct; 37(29):2661-2669. PubMed ID: 31411949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
    Gillison ML; Trotti AM; Harris J; Eisbruch A; Harari PM; Adelstein DJ; Jordan RCK; Zhao W; Sturgis EM; Burtness B; Ridge JA; Ringash J; Galvin J; Yao M; Koyfman SA; Blakaj DM; Razaq MA; Colevas AD; Beitler JJ; Jones CU; Dunlap NE; Seaward SA; Spencer S; Galloway TJ; Phan J; Dignam JJ; Le QT
    Lancet; 2019 Jan; 393(10166):40-50. PubMed ID: 30449625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trial.
    Nichols AC; Lang P; Prisman E; Berthelet E; Tran E; Hamilton S; Wu J; Fung K; de Almeida JR; Bayley A; Goldstein DP; Eskander A; Husain Z; Bahig H; Christopoulous A; Hier M; Sultanem K; Richardson K; Mlynarek A; Krishnan S; Le H; Yoo J; MacNeil SD; Mendez A; Winquist E; Read N; Venkatesan V; Kuruvilla S; Warner A; Mitchell S; Corsten M; Rajaraman M; Johnson-Obaseki S; Eapen L; Odell M; Chandarana S; Banerjee R; Dort J; Matthews TW; Hart R; Kerr P; Dowthwaite S; Gupta M; Zhang H; Wright J; Parker C; Wehrli B; Kwan K; Theurer J; Palma DA
    BMC Cancer; 2020 Feb; 20(1):125. PubMed ID: 32059705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiotherapy alone as a possible de-intensified treatment for human papillomavirus-related locally advanced oropharyngeal squamous cell carcinoma.
    Yamamoto Y; Takemoto N; Michiba T; Seo Y; Isohashi F; Otani K; Suzuki M; Fujii T; Yoshii T; Mitani K; Yasui T; Cho H; Tomita Y; Morii E; Teshima T; Ogawa K; Inohara H
    Int J Clin Oncol; 2019 Jun; 24(6):640-648. PubMed ID: 30694402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.